UNSPSC 51312706: Histapyrrodine hydrochloride

This classification denotes a histamine-1 receptor antagonist with the molecular formula C19H24N2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1W1AQ870ZC, chemically known as 1-pyrrolidineethanamine, n-phenyl-n-(phenylmethyl)-, monohydrochloride but more generally known as histapyrrodine hydrochloride, which bears US NIH Compound Identifier 160809. European Medicines Agency schedules Histapyrrodine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02526MIG.

UNSPSC 51312706 Histapyrrodine hydrochloride, a Commodity code, does not reflect the actual pharmaceutical and health-system procurement activity appearing in recent state and local solicitations tagged under this code. The opportunities posted show no connection to histapyrrodine hydrochloride specifically; instead, they cover naloxone distribution, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals and over-the-counter products. The code shows little relevant recent activity aligned with its nominal scope, and the mismatch between the code designation and the work being solicited suggests that state and local procurement systems may be applying this code inconsistently or erroneously to broader pharmacy and pharmaceutical-supply procurements that fall outside the narrower drug-substance classification the code's name implies.

The three visible opportunities span health departments, state HHS commissions, and cooperative purchasing alliances across Florida, Texas, and Minnesota. Seminole County, Florida issued an IFB on June 30, 2026, for 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023 (noting this deadline appears to be a data inconsistency in the source). Texas Health and Human Services Commission posted an RFI on April 3, 2026, to gather vendor capabilities on direct-to-manufacturer prescription programs without a binding timeline. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP on January 20, 2026, for generic multi-source pharmaceuticals and OTC products with a due date of March 26, 2026, structured across three authorized wholesalers and requiring NDC-level product specificity. None of these procurements directly target histapyrrodine hydrochloride; firms should verify code assignment with issuing bodies before pursuing opportunities under this designation.